We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.
We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.
We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.
We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.
We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.
We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.
We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.
We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.
We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.
We are studying whether adding abemaciclib to standard treatment improves outcomes for men with prostate cancer that has spread and is responsive to hormonal therapy. The trial also evaluates safety and patient quality of life.
We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.
We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.
We are studying a new treatment for children with severe hemophilia A or B to see if it is safer and more effective than standard care. This trial includes participants with or without inhibitors.
We are studying a new medication, frexalimab, to see if it helps preserve insulin production in young people with newly diagnosed type 1 diabetes. Participants will receive either the medication or a placebo while continuing their insulin therapy.
We are studying whether the combination of Venetoclax and Rituximab is more effective than standard treatments for patients with Waldenström’s Macroglobulinemia. This research aims to find better options for managing this condition.
We are studying a new cancer vaccine combined with two existing treatments for patients with unresectable liver cancer. The goal is to see if this combination improves survival and quality of life.
We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.
We are studying the safety and effects of a new treatment called SQY51 in children and adults with Duchenne Muscular Dystrophy. The goal is to see how it impacts muscle function and overall well-being.
We are studying a new medication, obexelimab, for people with IgG4-related disease to see if it helps prevent flare-ups after steroid treatment. We will also check how safe and well-tolerated it is for patients.
We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.